Novel Agents Are Changing the Prostate Cancer Treatment Landscape

Video

The addition of novel agents in the prostate cancer treatment landscape could create a shift in the way patients with advanced disease are treated, said Dr. Daniel George.

The addition of novel agents in the prostate cancer treatment landscape could create a shift in the way patients with advanced disease are treated, said Dr. Daniel George.

In an interview with CURE, George, a medical oncologist and the director of genitourinary oncology at Duke Cancer Institute, explained how patients can be treated earlier with new drugs that could prolong their lives.

Transcript:

Prostate cancer is really in a dynamic state right now, and it’s an exciting time for patients, caregivers and physicians alike. For the past probably 70 years, we’ve focused primarily on hormonal therapy, androgen deprivation therapy, particularly for patients with metastatic advanced prostate cancer.

Over the last few years, that landscape has changed with the approval of and the data showing clinical benefit associated with upfront use of docetaxel and then [Zytiga (abiraterone)], and most recently, with androgen receptor antagonists such as [Erleada (apalutamide)] and [Xtandi (enzalutamide)] in this landscape of patients with metastatic, hormone-sensitive prostate cancer.

And the repercussions of that are being felt downstream, so now we’re seeing patients enter into the castration-resistant prostate cancer setting having been exposed to these drugs, and I think we’re going to have an opportunity to treat earlier with some novel agents that are going to show promise in that post-(androgen receptor), post-chemotherapy setting, or with other cytotoxic agents that are maybe novel in the field and targeting the disease through radiopharmaceuticals like radium, also docetaxel or [(Jevtana (cabazitaxel)], as well as novel agents coming in that may be other ways of targeting, say, PSA [prostate specific antigens] and other strategies.

So, this is opening up room for clinical trials. Patients are going to live longer and have more time to go on those studies, which is exciting. We’re going to have an opportunity to treat patients earlier in the disease with life-prolonging therapies. And I think we’re going to begin to see some of these things translate into the curative setting, that’s probably one of the most exciting changes in the field that are coming, where we move from our investigational agents in the late stage all the way to the early stage, and this change in the landscape. It’s really a paradigm shift in how we think about managing our patients with advanced prostate cancer.

Related Videos
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Image of Dr. Minesh Mehta at ASCO 2024.
Image of a woman with blond hai
Image of a man with rectangular glasses and short dark hair.
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Related Content